BackAllogene Therapeutics Overview
Allogene Therapeutics Inc

Allogene Therapeutics Target Price

Allogene Therapeutics target price — quarterly history, peer benchmarks, and growth trends.

Get informed when a big investor buys or sells

+ Follow

Share Price

$1.99

Average Target Price

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-04-14Bernstein$3.8594% upsideOpen
2026-04-14Robert W. Baird$9353.4% upsideOpen
2024-05-16H.C. WainwrightDebjit Chattopadhyay$9353.4% upsideOpen
2024-05-14B.Riley FinancialKalpit Patel$7252.6% upsideOpen
2022-06-13Robert W. BairdJack Allen$11454.2% upsideOpen
2022-01-03GuggenheimMichael Schmidt$351663.2% upsideOpen
2021-12-03Canaccord GenuityJohn Newman$552670.8% upsideOpen
2021-10-08Roth CapitalAnthony Butler$351663.2% upsideOpen
2021-10-08Bank of America SecuritiesJason Gerberry$321512.1% upsideOpen
2021-10-08OppenheimerMark Breidenbach$401915.1% upsideOpen
2021-10-08JefferiesBiren Amin$301411.3% upsideOpen
2021-09-23Raymond JamesDane Leone$361713.6% upsideOpen

Allogene Therapeutics (ALLO) FAQ

Stockcircle tracks target price for Allogene Therapeutics (ALLO), including historical charts and peer comparisons when data is available. Check back as new filings are published, or open the stock overview for a broader fundamental snapshot.

This Target Price page is built for Allogene Therapeutics's historical target price trend and peer context. When enough reporting periods are on file, the charts below visualize how the metric has moved over time.

Use target price as one input alongside growth, profitability, valuation, and ownership activity. Stockcircle links related metric pages and the main ALLO overview so you can move from this figure to the surrounding analysis quickly.